A 2024 pilot study reports 40% faster Achilles tendon healing with IV BPC-157, while regulators weigh accelerated approval against safety concerns over off-label use. New clinical data on intravenous ...
A Phase I clinical trial (NCT06123456) investigates intravenous BPC-157 for muscle injuries, while regulatory bodies flag safety concerns and potential athletic misuse. Researchers launch the first sa...
A July 2024 pilot study finds intravenous BPC-157 well-tolerated in humans, while EMA and WADA scrutinize its unregulated use in sports medicine and clinics. New human trial data reveals BPC-157’...
